Bausch Health Companies Inc. Cash and Cash Equivalents
Bausch Health Companies Inc. (BHC) had Cash and Cash Equivalents of $1.82 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-07-30
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $1.82B.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $1.30B.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $1.31B.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $1.31B.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $1.82B 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $1.30B 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $1.31B 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $1.31B 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $1.73B 10-Q · filed 2026-07-30 | |
| 2025-03-31 | $1.13B 10-Q · filed 2026-04-30 | |
| 2024-12-31 | $1.18B 10-K · filed 2026-02-19 | |
| 2024-09-30 | $719.00M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $595.00M 10-Q · filed 2025-07-31 | |
| 2024-03-31 | $733.00M 10-Q · filed 2025-05-01 | |
| 2023-12-31 | $947.00M 10-K · filed 2026-02-19 | |
| 2023-09-30 | $760.00M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $579.00M 10-Q · filed 2024-08-01 | |
| 2023-03-31 | $518.00M 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $564.00M 10-K · filed 2025-02-20 | |
| 2022-09-30 | $486.00M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $659.00M 10-Q · filed 2023-08-03 | |
| 2022-03-31 | $1.25B 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $582.00M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $690.00M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $642.00M 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $679.00M 10-Q · filed 2022-05-10 | |
| 2020-12-31 | $605.00M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $977.00M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $896.00M 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $912.00M 10-Q · filed 2021-05-04 | |
| 2019-12-31 | $3.24B 8-K · filed 2022-05-11 | |
| 2019-09-30 | $825.00M 10-Q · filed 2020-11-03 | |
| 2019-06-30 | $878.00M 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $782.00M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $721.00M 8-K · filed 2021-05-04 | |
| 2018-09-30 | $973.00M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $838.00M 10-Q · filed 2019-08-06 | |
| 2018-03-31 | $909.00M 10-Q · filed 2019-05-06 | |
| 2017-12-31 | $720.00M 10-K · filed 2020-02-19 | |
| 2017-09-30 | $964.00M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $1.21B 10-Q · filed 2018-08-07 | |
| 2017-03-31 | $1.21B 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $542.00M 10-K · filed 2019-02-20 | |
| 2016-09-30 | $659.00M 10-Q · filed 2017-11-07 | $658.50M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $852.00M 10-Q · filed 2017-08-08 | $852.40M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $1.31B 10-Q · filed 2017-05-09 | $1.31B 10-Q · filed 2016-06-07 |
| 2015-12-31 | $597.00M 8-K · filed 2018-08-10 | $597.30M 10-K · filed 2016-04-29 |
| 2015-09-30 | $1.42B 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $958.00M 10-Q · filed 2016-08-09 | |
| 2015-03-31 | $1.86B 10-Q · filed 2016-06-07 | |
| 2014-12-31 | $323.00M 10-K · filed 2017-03-01 | $322.60M 10-K · filed 2015-02-25 |
| 2014-09-30 | $808.80M 10-Q · filed 2015-10-26 | |
| 2014-06-30 | $531.20M 10-Q · filed 2015-10-26 | |
| 2014-03-31 | $576.30M 10-Q · filed 2015-07-28 | |
| 2013-12-31 | $600.00M 10-K · filed 2017-03-01 | $600.34M 10-K · filed 2014-02-28 |
| 2013-09-30 | $596.30M 10-Q · filed 2014-10-24 | $596.35M 10-Q · filed 2013-11-01 |
| 2013-06-30 | $2.54B 10-Q · filed 2014-10-24 | $2.54B 10-Q · filed 2013-08-07 |
| 2013-03-31 | $413.70M 10-Q · filed 2014-08-01 | $413.74M 10-Q · filed 2013-05-03 |
| 2012-12-31 | $916.10M 10-K · filed 2016-04-29 | $916.09M 10-K · filed 2013-02-28 |
| 2012-09-30 | $257.73M 10-Q · filed 2013-11-01 | |
| 2012-06-30 | $395.27M 10-Q · filed 2013-11-01 | |
| 2012-03-31 | $330.48M 10-Q · filed 2013-08-07 | |
| 2011-12-31 | $164.10M 10-K · filed 2015-02-25 | $164.11M 10-K · filed 2012-02-29 |
| 2011-09-30 | $254.56M 10-Q · filed 2012-11-05 | |
| 2011-06-30 | $238.94M 10-Q · filed 2012-11-05 | |
| 2011-03-31 | $401.75M 10-Q · filed 2012-11-05 | |
| 2010-12-31 | $394.27M 10-K · filed 2014-02-28 | |
| 2010-09-30 | $592.65M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $176.57M 10-Q · filed 2011-11-04 | |
| 2010-03-31 | $102.89M 10-Q · filed 2011-08-08 | |
| 2009-12-31 | $114.46M 10-K · filed 2013-02-28 | |
| 2009-09-30 | $49.41M 10-Q · filed 2010-11-05 | |
| 2009-06-30 | $52.92M 10-Q · filed 2010-11-05 | |
| 2009-03-31 | $297.69M 10-Q · filed 2010-08-06 | |
| 2008-12-31 | $317.55M 10-K · filed 2012-02-29 | |
| 2007-12-31 | $433.64M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |